ATAI · AtaiBeckley Inc.
$7.35
+0.00% 2-day
End-of-day data · updated 2026-10-27
Market cap
$3B
Enterprise value
$3B
Trailing P/E
—
Forward P/E
-15.3
Dividend yield
—
Beta
1.55
Avg volume
15M
Employees
0K
Daily Change %
0.00%
5 Days Change
—
10 Days Change
—
30 Days Change
—
60 Days Change
—
Month to Day Change
0.00%
Year to Day Change
—
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Technical data is temporarily unavailable for ATAI.
Analyst sentiment over time — ATAI
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-12
Latest call per bank · past 12 months
Deutsche Bank
Hold$8.00
+8.8% vs priceJefferies
Hold$7.50
+2.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-12 | Deutsche Bank | Downgrade | Buy → Hold | $12.00 → $8.00 |
| 2026-07-20 | HC Wainwright & Co. | Downgrade | Buy → Neutral | $25.00 → $7.50 |
| 2026-07-17 | Guggenheim | Downgrade | Buy → Neutral | $0.00 |
| 2026-07-17 | Jones Trading | Downgrade | Buy → Hold | $0.00 |
| 2026-07-17 | Jefferies | Downgrade | Buy → Hold | $10.00 → $7.50 |
| 2026-07-16 | Maxim Group | Downgrade | Buy → Hold | $0.00 |
| 2026-07-16 | Canaccord Genuity | Downgrade | Buy → Hold | $0.00 → $8.00 |
| 2026-07-16 | Needham | Downgrade | Buy → Hold | $0.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
ATAI Price Chart
Loading chart for ATAI…
Fundamentals
About AtaiBeckley Inc.
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments. The company develops rapid-acting and durable therapies for conditions with limited treatment options. Its pipeline includes BPL-003 (mebufotenin benzoate), an intranasal formulation in Phase 2 and 3 clinical studies for treatment-resistant depression and alcohol use disorder; ELE-101, a serotonergic psychedelic for major depressive disorder; and RL-007, an orally bioavailable pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia. The company's pipeline also comprises VLS-01, an oral transmucosal film formulation of N, N-Dimethyltryptamine in Phase 2 clinical study for treatment-resistant depression; EMP-01, an oral formulation of the R-enantiomer of 3,4-methylenedioxy-methamphetamine in Phase 2 clinical study for social anxiety disorder; and EGX-A and EGX-B, non-hallucinogenic 5-HT2A receptor agonists for treatment-resistant depression. Additionally, it offers COMP360, a psilocybin therapy; and GRX-917, a treatment for anxiety, depression, and various neurological disorders. The company has additional operations in Germany and Canada. AtaiBeckley Inc. was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York. AtaiBeckley Inc. operates as a subsidiary of Eli Lilly and Company.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 14.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 5.0% YTD
MRNA
Moderna, Inc.
$79B 574.3% YTD
ARGX
argenx SE
$55B 3.4% YTD
ONC
BeOne Medicines Ltd.
$42B 22.1% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.9% YTD
RPRX
Royalty Pharma plc
$37B 69.9% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.